To study whether PPP3CB Ex16 accumulation occurs at disease progression under EGFR TKI treatment, we took advantage of a retrospective cohort of 43 EGFR-mutant lung adenocarcinoma patients with paired tissue sections (pre- and post-progression after EGFR TKI treatment). Here, PPP3CB is linked to lung adenocarcinoma.